Literature DB >> 20226755

The kinetic mechanism of human uridine phosphorylase 1: Towards the development of enzyme inhibitors for cancer chemotherapy.

Daiana Renck1, Rodrigo G Ducati, Mario S Palma, Diógenes S Santos, Luiz A Basso.   

Abstract

Uridine phosphorylase (UP) is a key enzyme in the pyrimidine salvage pathway, catalyzing the reversible phosphorolysis of uridine to uracil and ribose-1-phosphate (R1P). The human UP type 1 (hUP1) is a molecular target for the design of inhibitors intended to boost endogenous uridine levels to rescue normal tissues from the toxicity of fluoropyrimidine nucleoside chemotherapeutic agents, such as capecitabine and 5-fluorouracil. Here, we describe a method to obtain homogeneous recombinant hUP1, and present initial velocity, product inhibition, and equilibrium binding data. These results suggest that hUP1 catalyzes uridine phosphorolysis by a steady-state ordered bi bi kinetic mechanism, in which inorganic phosphate binds first followed by the binding of uridine, and uracil dissociates first, followed by R1P release. Fluorescence titration at equilibrium showed cooperative binding of either P(i) or R1P binding to hUP1. Amino acid residues involved in either catalysis or substrate binding were proposed based on pH-rate profiles. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20226755     DOI: 10.1016/j.abb.2010.03.004

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  10 in total

1.  Uridine phosphorylase from Trypanosoma cruzi: kinetic and chemical mechanisms.

Authors:  Rafael G Silva; Vern L Schramm
Journal:  Biochemistry       Date:  2011-09-27       Impact factor: 3.162

2.  Metabolites modulate the functional state of human uridine phosphorylase I.

Authors:  Yu-Ting Huang; Pei-Chin Yeh; Shih-Chun Lan; Pei-Fen Liu
Journal:  Protein Sci       Date:  2020-09-28       Impact factor: 6.725

3.  The crystal structure of Streptococcus pyogenes uridine phosphorylase reveals a distinct subfamily of nucleoside phosphorylases.

Authors:  Timothy H Tran; S Christoffersen; Paula W Allan; William B Parker; Jure Piskur; I Serra; M Terreni; Steven E Ealick
Journal:  Biochemistry       Date:  2011-07-08       Impact factor: 3.162

4.  A novel structural mechanism for redox regulation of uridine phosphorylase 2 activity.

Authors:  Tarmo P Roosild; Samantha Castronovo; Adelbert Villoso; Amy Ziemba; Giuseppe Pizzorno
Journal:  J Struct Biol       Date:  2011-08-10       Impact factor: 2.867

5.  Transition-state analysis of Trypanosoma cruzi uridine phosphorylase-catalyzed arsenolysis of uridine.

Authors:  Rafael G Silva; Mathew J Vetticatt; Emilio F Merino; Maria B Cassera; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2011-06-03       Impact factor: 15.419

6.  Active site conformational dynamics in human uridine phosphorylase 1.

Authors:  Tarmo P Roosild; Samantha Castronovo
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

7.  Pan-pathway based interaction profiling of FDA-approved nucleoside and nucleobase analogs with enzymes of the human nucleotide metabolism.

Authors:  Louise Egeblad; Martin Welin; Susanne Flodin; Susanne Gräslund; Liya Wang; Jan Balzarini; Staffan Eriksson; Pär Nordlund
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

8.  Engineering of the Recombinant Expression and PEGylation Efficiency of the Therapeutic Enzyme Human Thymidine Phosphorylase.

Authors:  Christos S Karamitros; Catrina M Somody; Giulia Agnello; Scott Rowlinson
Journal:  Front Bioeng Biotechnol       Date:  2021-12-17

Review 9.  Structure, Oligomerization and Activity Modulation in N-Ribohydrolases.

Authors:  Massimo Degano
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

10.  Biochemical characterization of uracil phosphoribosyltransferase from Mycobacterium tuberculosis.

Authors:  Anne Drumond Villela; Rodrigo Gay Ducati; Leonardo Astolfi Rosado; Carlos Junior Bloch; Maura Vianna Prates; Danieli Cristina Gonçalves; Carlos Henrique Inacio Ramos; Luiz Augusto Basso; Diogenes Santiago Santos
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.